# EDGAR Filing Document

**Accession Number:** 0001540159
**File Stem:** 0001171843-25-005749
**Filing Date:** 2025-9
**Character Count:** 2124
**Document Hash:** 951b8dd116b231120c0051156a0b440e
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001171843-25-005749.hdr.sgml**: 20251205

**ACCESSION NUMBER**: 0001171843-25-005749

**CONFORMED SUBMISSION TYPE**: CORRESP

**PUBLIC DOCUMENT COUNT**: 1

**FILED AS OF DATE**: 20250905

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Edesa Biotech, Inc.
- **CENTRAL INDEX KEY:** 0001540159
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** A1
- **FISCAL YEAR END:** 0930

**FILING VALUES:**
- **FORM TYPE:** CORRESP

**BUSINESS ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** 100 SPY COURT
- **CITY:** MARKHAM
- **PROVINCE COUNTRY:** A6
- **BUSINESS PHONE:** (905) 475-1234

**MAIL ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** 100 SPY COURT
- **CITY:** MARKHAM
- **PROVINCE COUNTRY:** A6

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Stellar Biotechnologies, Inc.
- **DATE OF NAME CHANGE:** 20120120

**Edesa Biotech, Inc.** 

**100 Spy Court**

**Markham, Ontario, Canada L3R 5H6**

September 5, 2025

**<u>VIA EDGAR</u>**

United States Securities and Exchange Commission

Division of Corporation Finance

100 F Street, N.E.

Washington, D.C. 20549

---

| | |
|:---|:---|
| **Re:** | **Edesa Biotech, Inc.** |

---

**Registration Statement on Form S-3 (File No. 333-288966)**

**Filed on July 25, 2025** 

Ladies and Gentlemen:

In accordance with Rule 461 under the Securities Act of 1933, as amended, Edesa Biotech, Inc. (the "<u>Company</u>") hereby requests that the above-referenced Registration Statement (the "<u>Registration Statement</u>") be declared effective by the Securities and Exchange Commission at 4:00 p.m., Eastern Time, on September 9, 2025, or as soon as practicable thereafter.

Please call Tracy Buffer of Lowenstein Sandler LLP at (973) 597-2434 to confirm the effectiveness of the Registration Statement or with any questions.

---

| |
|:---|
| Very truly yours, |
| EDESA BIOTECH, INC. |
| *By: <u>/s/ Peter Weiler</u>* |
| Name: Peter Weiler |
| Title: Chief Financial Officer |

---